Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?

Abstract excerpt

The robust clinical activity of imatinib and trastuzumab for treatment of chronic myeloid leukemia, gastrointestinal stromal tumors, and breast cancer has demonstrated that blocking pathogenic tyrosine kinases can alter the natural history of human tumors. On the other hand, EGF receptor inhibitors have shown overall modest activity. The contrast in the development of these agents implies that both molecular...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibodies, Monoclonal, Humanized
• Share to Benzamides
• Share to Clinical Trials as Topic